Portfolio

Quantum Technology Partners invests in  early stage technology and life sciences companies.

BiPar Sciences, Inc., headquartered in South San Francisco, CA, is a privately held biopharmaceutical company engaged in the development and commercialization of novel therapies to treat cancers for which current therapies are inadequate and/or are commonly associated with debilitating side effects.  The Company’s initial focus is the  development and commercialization of three pre clinical, small molecule drug candidates for the treatment of breast and ovarian cancers.  BiPar intends to expand development efforts to a broader group of cancers as its initial drug candidates enter the clinic. Co-investors include Domain Associates, Vulcan Capital, Canaan Partners, Asset Management Company and PolyTechnos Venture-Partners.

Corium International, Inc., headquartered in Menlo Park, CA is engaged in the research, development and manufacture of advanced transdermal drug delivery technologies and products. Using its proprietary delivery technologies and its development and manufacturing expertise, Corium has developed a number of active and passive transdermal products with enhanced therapeutic or safety profiles. Corium merged with StrataGent Life Sciences, Inc., a Quantum portfolio company. StrataGent is a specialty pharmaceutical company developing therapeutic products based on its revolutionary transdermal drug delivery technology. StrataGent’s low-profile, programmable, non-invasive, patch device is uniquely able to painlessly deliver most drugs, including injectibles, with fast onset and optimized dosage profiles. Quantum led the initial StrataGent financing and participated in the follow-on investments of StrataGent and the post-merger investment in Corium, both of which were led by Essex Woodlands Health Ventures.

IMI Intelligent Medical Implants AG, based in Zug, Switzerland with its subsidiary IIP-Technologies GmbH, based in Bonn, Germany is developing a Learning Retinal Implant System, the first product of its developing technology platform in neurostimulation. Co-investors include Abingworth, Global Life Science Ventures, PolyTechnos Venture-Partners and Valtronic SA.

Magnolia Broadband, Inc., based in Bedminster, NJ, is a developer of integrated, multi-transceiver, low-power RF chips for mobile phones and is pioneering development of radio chips for cell phones that employ smart antennas, a major breakthrough for the wireless industry. Co-investors include ECentury Capital, SCP Private Equity Partners, Selway Partners, Draper Fisher Jurvetson Gotham, Silverstar Holdings, UniQuest and Intel Capital.

SPI Lasers Plc  (formerly Southampton Photonics), based in Southampton, U.K., is positioned to be the leader in high power fiber lasers and are expanding the applications space for fiber lasers, with powers from mWs to KWs, while delivering state-of-the-art products, components and subsystems which are driving down the cost of ownership to its customers in the industrial, aerospace, analytical, sensing and communications markets. SPI fiber lasers deliver higher power, higher reliability as well as greater wavelength accuracy and stability than their competitors and do not require water cooling. Co-investors include Advent Venture Partners, Amadeus Capital Partners, InterWest Partners and Sevin Rosen Funds. (London Stock Exchange|AIM:SPIL.L)

Vaxart, Inc., located in San Francisco, California, is a biotechnology company developing oral vaccinations against infectious diseases. Vaxart's proprietary technology permits rapid, low cost, high volume production of orally delivered vaccines for a wide range of infectious agents. Quantum co-led the Series A financing with Life Science Angels. Bay Partners also participated in the financing.